Capital Nasdaq Financials
| 00678 Etf | TWD 28.64 0.48 1.65% |
Capital |
The data published in Capital Nasdaq's official financial statements typically reflect Capital Nasdaq's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Capital Nasdaq's quantitative information. For example, before you start analyzing numbers published by Capital accountants, it's essential to understand Capital Nasdaq's liquidity, profitability, and earnings quality within the context of the Capital Investment Trust Co., Ltd space in which it operates.
Please note, the imprecision that can be found in Capital Nasdaq's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Capital Nasdaq Biotechnology. Check Capital Nasdaq's Beneish M Score to see the likelihood of Capital Nasdaq's management manipulating its earnings.
Capital Nasdaq Etf Summary
CAPITAL SECURITIES is traded on Taiwan Stock Exchange in Taiwan.| Instrument | Taiwan Etf |
| Exchange | Taiwan Stock Exchange |
| Region | Others |
| Investment Issuer | Others |
| Etf Family | Capital Investment Trust Co., Ltd |
| Benchmark | Dow Jones Industrial |
| Currency | TWD - New Taiwan Dollar |
Capital Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Capital Nasdaq's current stock value. Our valuation model uses many indicators to compare Capital Nasdaq value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Capital Nasdaq competition to find correlations between indicators driving Capital Nasdaq's intrinsic value. More Info.Capital Nasdaq Biotechnology is fourth largest ETF in one year return as compared to similar ETFs. It also is fourth largest ETF in three year return as compared to similar ETFs reporting about 0.32 of Three Year Return per One Year Return. The ratio of One Year Return to Three Year Return for Capital Nasdaq Biotechnology is roughly 3.10 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Capital Nasdaq's earnings, one of the primary drivers of an investment's value.Capital Nasdaq Biote Systematic Risk
Capital Nasdaq's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Capital Nasdaq volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Capital Nasdaq Biote correlated with the market. If Beta is less than 0 Capital Nasdaq generally moves in the opposite direction as compared to the market. If Capital Nasdaq Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Capital Nasdaq Biote is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Capital Nasdaq is generally in the same direction as the market. If Beta > 1 Capital Nasdaq moves generally in the same direction as, but more than the movement of the benchmark.
Capital Nasdaq March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Capital Nasdaq help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Capital Nasdaq Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Capital Nasdaq Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Capital Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Capital Nasdaq's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 4.66 | |||
| Value At Risk | (1.87) | |||
| Potential Upside | 1.63 |
Other Information on Investing in Capital Etf
Capital Nasdaq financial ratios help investors to determine whether Capital Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Capital with respect to the benefits of owning Capital Nasdaq security.